Belgian Capital Markets Stock News

If you're not sure where to start when looking for the next multi-bagger, there are a few key trends you should keep an...

What trends should we look for it we want to identify stocks that can multiply in value over the long term? Ideally, a...

Key Insights Institutions' substantial holdings in Azelis Group implies that they have significant influence over the...

Warehouses De Pauw (WDP) recently reported earnings for the nine months ended September 30, 2025, posting sales of €335.6 million, up from €284.28 million a year earlier, but net income fell to €246.68 million compared to €306.32 million in the prior period. In addition, Clifford Chance announced it advised on WDP’s inaugural €500 million green senior unsecured bond issuance under its EMTN programme, following a Moody’s upgrade of WDP’s long-term issuer rating to A3 with a stable...

On October 13, 2025, UCB announced that Neurology had published favorable results from a multicenter retrospective chart review study of its investigational pyrimidine nucleoside and/or nucleotide therapy in patients with thymidine kinase 2 deficiency (TK2d), showing that 29% (6 out of 21) of treated individuals experienced reduced need for ventilatory support and most adverse events were mild. An interesting aspect of the study is the potential clinical impact on this rare neuromuscular...

Warehouses De Pauw (ENXTBR:WDP) just posted results for the nine months ending September 2025. Sales climbed compared to last year, while net income and earnings per share slipped during the same stretch. See our latest analysis for Warehouses De Pauw. Warehouses De Pauw’s 8.5% share price return over the last 90 days suggests growing optimism, even though the total shareholder return for the past year has been a more modest 2.1%. In the broader context, recent gains appear to reflect renewed...

UCB (ENXTBR:UCB) just shared results from a multicenter study published in Neurology, highlighting that a new investigational therapy for TK2 deficiency showed some treated patients needed less ventilatory support, with mostly mild side effects. See our latest analysis for UCB. Despite some recent pullbacks, UCB’s share price has surged with a 22.5% gain over the past month and a remarkable 42.2% in the last 90 days. Momentum appears to be on the upswing, and when you look at the long game,...

In the past week, Solvay SA reported a year-over-year drop in second-quarter 2025 earnings, with both underlying net sales and EBITDA affected by difficult market conditions. An interesting development is Solvay's achievement of €29 million in cost savings during the quarter while pressing ahead with rare earth and soda ash projects intended to reinforce its market standing. We'll explore how Solvay's ongoing focus on operational efficiency and cost-saving progress informs its investment...

argenx SE recently presented new data for VYVGART® and its efgartigimod pipeline at the 2025 American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) Annual Meeting and the Myasthenia Gravis Foundation of America (MGFA) Scientific Session in San Francisco. These clinical updates, which include pivotal trial and real-world data across multiple patient subgroups, highlight advances in treating generalized myasthenia gravis and support ongoing innovation in rare neuromuscular...

D'Ieteren Group SA ( EBR:DIE ), is not the largest company out there, but it saw significant share price movement...

For many investors, the main point of stock picking is to generate higher returns than the overall market. But its...

When close to half the companies in Belgium have price-to-earnings ratios (or "P/E's") below 15x, you may consider Elia...

UCB SA ( EBR:UCB ) shares have continued their recent momentum with a 25% gain in the last month alone. Looking back a...

Stock pickers are generally looking for stocks that will outperform the broader market. And the truth is, you can make...

Umicore SA ( EBR:UMI ) shares have had a really impressive month, gaining 25% after a shaky period beforehand. Looking...

If you are weighing your next move with argenx stock, you are definitely not alone. After all, this is a company that has rewarded patience. Just looking at the numbers, argenx has surged 41.0% in the past year and an incredible 195.9% over five years. Even in the shorter term, the momentum is hard to ignore, with a 1.0% gain over the past week and a solid 4.5% for the month. With returns like these, it is no wonder there is so much buzz around what is driving the growth, how much upside...

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...

In late September 2025, Anheuser-Busch announced a US$7.4 million investment to upgrade brewing and packaging equipment at its Los Angeles brewery to boost Michelob ULTRA production in response to demand for new can sizes and formats as part of its wider “Brewing Futures” initiative, with over US$300 million earmarked for U.S. operations. This investment, along with a US$9 million expansion for Beyond Beer products in New York, highlights AB InBev’s focus on supporting manufacturing jobs,...

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...

Readers hoping to buy Melexis NV ( EBR:MELE ) for its dividend will need to make their move shortly, as the stock is...

In October 2025, Umicore announced it had sold its permanently tied up gold inventories from its Jewelry & Industrial Metals and Precious Metals Refining business units, generating €410 million in net proceeds and a significant after-tax capital gain of €370 million. This move enables Umicore to strengthen its balance sheet and optimize financing costs by shifting to revolving metal leases, increasing financial flexibility while maintaining operational effectiveness. Let's explore how...

Melexis NV's ( EBR:MELE ) investors are due to receive a payment of €0.91 per share on 16th of October. This means the...

Umicore (ENXTBR:UMI) shares have drawn renewed investor interest lately, with quarterly results offering a clearer look at both recent profit trends and ongoing shifts in the materials sector. Investors are monitoring how performance metrics play into broader market sentiment. See our latest analysis for Umicore. Umicore’s share price has gained strong momentum lately, jumping over 59% year-to-date and up 20% in the last month alone. While the one-year total shareholder return stands at...

If you own Colruyt Group stock, or are watching from the sidelines for the right entry point, you are not alone. The company’s recent performance has definitely raised a few eyebrows and stirred up some debate. Over the past year, Colruyt shares have shed 22.5%, continuing a downward trend that deepened with a 16.2% drop over the last 30 days alone. Year to date, the stock is off by 12.8%. That sounds rough, but if you zoom out a bit, you’ll see a three-year return of 53.6%, demonstrating...